Stock 300391 CHANGJIANG PHARMACEUTICAL GROUP CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

News Changjiang Pharmaceutical Group Co., Ltd.

Equities

300391

CNE100001XN8

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-05-27 pm EDT 		5-day change 1st Jan Change
3.39 CNY -0.59% Intraday chart for Changjiang Pharmaceutical Group Co., Ltd. -3.97% -56.20%
May. 08 Yichang HEC Still Negotiating Merger Deal with Sunshine Lake Pharma MT
Apr. 29 Changjiang Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Yichang HEC Still Negotiating Merger Deal with Sunshine Lake Pharma
MT
Changjiang Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Changjiang Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Yichang Hec Changjiang Pharmaceutical Updates on Possible Merger with Sunshine Lake Pharma
MT
Yichang Hec Changjiang Pharmaceutical's Net Profit Surges in 2023 as Revenue Jumps
MT
YiChang HEC ChangJiang Pharmaceutical's Profit Surges in 2023
MT
Yichang Hec Changjiang Pharmaceutical Expects Up to 2,627% Profit Surge in 2023
MT
HEC ChangJiang Pharmaceutical Increases Transaction Limits Under 2 Contracts
MT
Changjiang Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
HEC ChangJiang Pharmaceutical's Insulin Injection Cleared for Market Launch in China
MT
HEC ChangJiang Pharmaceutical Returns to Profit on Surge in Anti-Viral Drug Sales
MT
Changjiang Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
China Greenlights New Drug Application for HEC ChangJiang Pharmaceutical's Hepatitis C Drug
MT
HEC ChangJiang Pharmaceutical Forecasts Surge in H1 Profit; Shares Rise 5%
MT
Yucong Tianshun No. 2 Private Equity Securities Investment Fund managed by Shanghai Yucong Asset Management Co., Ltd completed the acquisition of 5.9942% stake in Changjiang Pharmaceutical Group Co., Ltd. from Changxing Shengshi Fenghua Business Co., Ltd.
CI
HEC ChangJiang Pharma Repurchases $400 Million Convertible Bonds Issued to Blackstone
MT
Yucong Tianshun No. 2 Private Equity Securities Investment Fund managed by Shanghai Yucong Asset Management Co., Ltd signed Share Transfer Agreement to acquire 5.9942% stake in Changjiang Pharmaceutical Group Co., Ltd. from Changxing Shengshi Fenghua Business Co., Ltd. for CNY 154.14 million.
CI
Changjiang Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Changjiang Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Changjiang Pharma Units Sign 359 Million Yuan Contracts
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 300391 Stock
  4. News Changjiang Pharmaceutical Group Co., Ltd.